Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Head and Neck Pathology
|
June 7, 2020
FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones
Ioannis G Koutlas, Damon R Olson, Jawhar Rawwas
Experimental Cell Research
|
October 29, 2008
Regulation of CRABP-II expression by MycN in Wilms tumor
Anu Gupta, Patricia Kessler, Jawhar Rawwas, et al.
Journal of Pediatric Hematology/Oncology Nursing
|
February 19, 2026
Naxitamab for Relapsed/Refractory Neuroblastoma
Teresa Herriage, Jawhar Rawwas, Adam Sterman, et al.
Cancer Research
|
August 17, 2006
Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma
Anu Gupta, Bryan R G Williams, Samir M Hanash, et al.
Pediatric Transplantation
|
June 20, 2018
Hepatosplenic γδ T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults
Sheila S McThenia, Jawhar Rawwas, Jennifer L Oliveira, et al.
Pediatric Blood & Cancer
|
February 12, 2016
Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence
Navin Pinto, Jodi R Mayfield, Gordana Raca, et al.
The American Journal of Surgical Pathology
|
July 31, 2023
"Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications
Pedram Argani, L Jeffrey Medeiros, Andres Matoso, et al.
International Journal of Cancer
|
May 12, 2020
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Elizabeth C Lewis, Jacqueline M Kraveka, William Ferguson, et al.
NPJ Precision Oncology
|
July 9, 2025
RAS pathway targeted therapy in patients with DICER1-associated sarcomas
Lindy Zhang, Paige H R Mallinger, Serena Zhou, et al.
International Journal of Cancer
|
May 29, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Don Eslin, Peter E Zage, Genevieve Bergendahl, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Head and Neck Pathology
|
June 7, 2020
FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones
Ioannis G Koutlas, Damon R Olson, Jawhar Rawwas
Experimental Cell Research
|
October 29, 2008
Regulation of CRABP-II expression by MycN in Wilms tumor
Anu Gupta, Patricia Kessler, Jawhar Rawwas, et al.
Journal of Pediatric Hematology/Oncology Nursing
|
February 19, 2026
Naxitamab for Relapsed/Refractory Neuroblastoma
Teresa Herriage, Jawhar Rawwas, Adam Sterman, et al.
Cancer Research
|
August 17, 2006
Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma
Anu Gupta, Bryan R G Williams, Samir M Hanash, et al.
Pediatric Transplantation
|
June 20, 2018
Hepatosplenic γδ T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults
Sheila S McThenia, Jawhar Rawwas, Jennifer L Oliveira, et al.
Pediatric Blood & Cancer
|
February 12, 2016
Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence
Navin Pinto, Jodi R Mayfield, Gordana Raca, et al.
The American Journal of Surgical Pathology
|
July 31, 2023
"Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications
Pedram Argani, L Jeffrey Medeiros, Andres Matoso, et al.
International Journal of Cancer
|
May 12, 2020
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Elizabeth C Lewis, Jacqueline M Kraveka, William Ferguson, et al.
NPJ Precision Oncology
|
July 9, 2025
RAS pathway targeted therapy in patients with DICER1-associated sarcomas
Lindy Zhang, Paige H R Mallinger, Serena Zhou, et al.
International Journal of Cancer
|
May 29, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Don Eslin, Peter E Zage, Genevieve Bergendahl, et al.
Page
of 2